Neuronal voltage-gated N-type (Ca v 2.2) calcium channels are expressed throughout the nervous system and regulate neurotransmitter release and hence synaptic transmission. They are predominantly modulated via G protein-coupled receptor activated pathways, and the well characterized Gbg subunits inhibit Ca v 2.2 currents. Analgesic a-conotoxin Vc1.1, a peptide from predatory marine cone snail venom, inhibits Ca v 2.2 channels by activating pertussis toxin-sensitive G i/o proteins via the GABA B receptor (GABA B R) and potently suppresses pain in rat models. Using a heterologous GABA B R expression system, electrophysiology, and mutagenesis, we showed a-conotoxin Vc1.1 modulates Ca v 2.2 via a different pathway from that of the GABA B R agonists GABA and baclofen. In contrast to GABA and baclofen, Vc1.1 changes Ca v 2.2 channel kinetics by increasing the rate of activation and shifting its halfmaximum inactivation to a more hyperpolarized potential. We then systematically truncated the GABA B1a C terminus and discovered that removing the proximal carboxyl terminus of the GABA B1a subunit significantly reduced Vc1.1 inhibition of Ca v 2.2 currents. We propose a novel mechanism by which Vc1.1 activates GABA B R and requires the GABA B1a proximal carboxyl terminus domain to inhibit Ca v 2.2 channels. These findings provide important insights into how GABA B Rs mediate Ca v 2.2 channel inhibition and alter nociceptive transmission.
Introduction
The G protein-coupled GABA B receptor (GABA B R) is widely expressed in the brain and plays an important role in regulating neurotransmission. The neurotransmitter GABA binds to GABA B Rs, leading to activation of G i/o G proteins, which dissociate into activated Ga i/o -GTP and the Gbg dimer. Ga i/o inhibits adenylyl cyclase, while the Gbg dimer inhibits high voltage-activated (HVA) calcium channels (MenonJohansson et al., 1993; Ikeda, 1996; Sun and Chiu, 1999) and activates G protein-gated inwardly rectifying potassium (GIRK) channels (Luscher and Slesinger, 2010) . GABA B R is a potential target for drugs that treat neurologic illnesses, such as pain, epilepsy, spasticity, and psychiatric disorders (Marshall et al., 1999; Bowery et al., 2002) . For example, inhibition of presynaptic HVA calcium channels, such as Ca v 2.2, has been linked to suppression of neurotransmitter release and block of nociception transmission (Winquist et al., 2005; Gribkoff, 2006) .
A 16-amino acid peptide derived from venom of the marine cone snail Conus victoriae, a-conotoxin Vc1.1 (Clark et al., 2006) , potently suppresses neuropathic pain when injected intramuscularly near the site of injury in rat models (Sandall et al., 2003; Satkunanathan et al., 2005; Klimis et al., 2011) . Initially, the analgesic effect was attributed to inhibition of neuronal nicotinic acetylcholine receptors (Satkunanathan et al., 2005; Livett et al., 2006; Vincler et al., 2006) . However, subsequent studies using rodent dorsal root ganglion (DRG) neurons demonstrated that the analgesic effect of Vc1.1 is more likely due to inhibition of Ca v 2.2 channels via GABA B R activation (Callaghan et al., 2008; Callaghan and Adams, 2010) . In support of this, small interfering RNA knockdown of GABA B R expression in DRG neurons significantly reduced Vc1.1-dependent inhibition of Ca v 2.2 (Cuny et al., 2012) . In addition, Vc1.1 inhibition of Ca v 2.2 can be reconstituted in human embryonic kidney 293 (HEK293) cells coexpressing only GABA B Rs and Ca v 2.2 channels (Cuny et al., 2012) . Thus, Vc1.1 inhibition minimally requires both GABA B R subunits, G proteins, and Ca v 2.2 channels. We have recently shown that Vc1.1 also inhibits Ca v 2.3 but not Ca v 2.1 channels via GABA B R activation in HEK293 cells (Berecki et al., 2014) . However, little is known about how Vc1.1 activates GABA B Rs.
Here, we examined the mechanism of Vc1.1 inhibition in a heterologous expression system that reconstitutes the human Ca v 2.2/GABA B R signaling pathway (Cuny et al., 2012) . We provide further details of the mechanism by which Vc1.1 inhibits Ca v 2.2 channels via activation of GABA B R. We discovered that Vc1.1 activation of GABA B Rs occurs via a signaling pathway distinct from that of classic agonists, such as GABA and baclofen. Our findings support an emerging model of signaling bias, which results from allosteric ligand binding to G protein-coupled receptors (GPCRs) at sites different to endogenous ligand binding (Wootten et al., 2013) . Numerous studies have shown that agonists do not uniformly activate cellular signaling pathways (biased signaling), and GPCRs produce multiple effector pathways due to their association with secondary messengers, such as G proteins and b-arrestin (Bohn and McDonald, 2010; Rajagopal et al., 2011) .
Materials and Methods
Clones, Cell Culture, and Transfections. Human GABA B1 and GABA B2 subunit cDNA clones were obtained from OriGene Technologies, Inc. (Rockville, MD). The rat Ca v 2.2 channel, a 1B splice variant e37a, and auxiliary subunit b 3 were provided by Dr. Diane Lipscombe (Brown University), and the auxiliary subunit a 2 d 1 was provided by Dr. Gerald W. Zamponi (University of Calgary). Rat wild-type GABA B R and the mutant GABA B1a -ΔPCT, GABA B1a -Δ887, GABA B1a -Δ863 (Laviv et al., 2011) , and GABA B2 -R576D (Binet et al., 2007; Boyer et al., 2009 ) constructs have been described previously. Site-directed mutagenesis on GABA B1a was carried out using the GENEART Site-Directed Mutagenesis System Kit (Invitrogen/Life Technologies, Mulgrave, VIC, Australia) with the following primers:
59-TCTCATATGGCTCCAGTGCACCAGCCTTGTCAAACCG-39 and 59-CGGTTTGACAAGGCTGGTGCACTGGAGCCATATGAGA-39 for rat GABA B1a -S270A; and 59-CCTTATGCCTGGCTGCGCCTCTGTCTCC-ACGCTGG-39 and 59-CCAGCGTGGAGACAGAGGCGCAGCCAGGCA-TAAGG-39 for human GABA B1a -S246A. Correct mutation of the cDNAs was verified by automated DNA sequencing (Australian Genome Research Facility, Melbourne, VIC, Australia).
HEK293 cells expressing the SV40 large T-antigen (HEK293T) were cultured in Dulbecco's Modified Eagle's Medium (Invitrogen Australia Pty Ltd., Mulgrave, VIC, Australia) supplemented with 10% (v/v) fetal bovine serum (Invitrogen), 50 IU/ml penicillin, and 50 mg/ml streptomycin (Invitrogen) at 37°C in 5% CO 2 . HEK293 cells stably expressing human Ca v 2.2 channels (a 1B , a 2 d1, and b 3 subunits) were obtained from Merck (Rahway, NJ) and cultured according to procedures described previously (Dai et al., 2008) .
HEK293 cells expressing the SV40 large T-antigen were transiently cotransfected by calcium phosphate transfection, as described previously (Cuny et al., 2012) , with plasmid cDNAs (3 mg) encoding the rat Ca v 2.2 channel a 1B , a 2 d1, and b 1b auxiliary subunits, 5 mg rat wild-type or mutant GABA B1a R, GABA B2 R, and 0.1 mg enhanced green fluorescent protein. Stable Ca v 2.2 expressing HEK293 cells were seeded into 12 well plates and transiently cotransfected with human GABA B1 and GABA B2 subunits (2 mg each) and 0.2 mg enhanced green fluorescent protein using Lipofectamine (Invitrogen) according to the manufacturer's protocol.
Two to three days after transfection, cells were seeded onto glass coverslips and incubated at 37°C in 5% CO 2 for at least 6 hours before recording. The effects of Vc1.1 or baclofen on the percentage of peak current inhibition were independent of either transfection method or cell line (transiently or stably expressed Ca v 2.2) used.
Electrophysiological Patch-Clamp Recording. Whole-cell patch-clamp recording from transfected HEK293 cells has been described previously (Cuny et al., 2012) . Briefly, HEK293 cells were (C) Bar graph of inhibition of peak current amplitude by 200 nM Vc1.1 (41.0 6 5.3%), 50 mM baclofen (61.5 6 5.7%), 10 mM GABA (69.6 6 2.3%), and 200 nM Vc1.1 plus 50 mM baclofen (78.1 6 3.6%). Number of experiments is indicated in parentheses. Data represent mean 6 S.E.M. **P , 0.01; ***P , 0.001 versus Vc1.1, one-way analysis of variance. (D) Concentration-response relationship for Vc1.1 inhibition of peak current in HEK293 cells coexpressing GABA B R and Ca v 2.2 channels with an IC 50 of 19.1 nM and Hill slope of -1 (n = 6-7 cells per data point).
superfused with a solution containing (in mM): NaCl 90, BaCl 2 10, CsCl 5, TEA-Cl 30, MgCl 2 1, D-glucose 10, and HEPES 10, pH 7.4 with TEA-OH. Fire-polished borosilicate patch pipettes (2-3 MV tip resistance) were filled with a solution containing (in mM): K-gluconate 120, NaCl 5, MgCl 2 2, EGTA 5, MgATP 2, Na 2 GTP 0.6, and HEPES 10, pH 7.2 with CsOH. Typically, cells were voltage clamped at 290 mV (adjusted for liquid junction potential) and membrane currents were elicited by 200-millisecond step depolarizations to either 15 or 110 mV at 0.1 or 0.05 Hz. Whole-cell patch-clamp recordings were made using a MultiClamp 700B amplifier (Molecular Devices, Sunnyvale, CA) controlled by a Clampex 10/DigiData1332 acquisition system at room temperature (22-23°C). Membrane currents were filtered at 1 or 2 kHz and sampled at 5 or 8 kHz. Leak and capacitive currents were subtracted using a 2P/4 pulse protocol. Data were stored digitally on a computer for further analysis. Peak current amplitude in response to the depolarizing pulse was measured once a steady state was achieved (3-5 minutes).
Data Analysis and Statistics. Data were analyzed using Clampfit 10 software (Molecular Devices), 2007 Excel (Microsoft, Seattle, WA), and Prism 6 (GraphPad Software Inc., La Jolla, CA). Peak current amplitude in response to a depolarization step was calculated and plotted against time. A steady-state peak current was recorded for at least 2-3 minutes before the drug was applied.
Activation curves were plotted from the I-V relationship by calculating conductance using the equation
where G is the conductance, V t is the test potential, and E rev is the extrapolated reversal potential.
The voltage dependence of the peak Ca v 2.2 current density was fitted with the Boltzmann function
where G max is the maximum conductance, V 0.5 is the midpoint or halfmaximal activation, and k is the slope factor.
For steady-state inactivation (SSI), data were fitted with a single Boltzmann function
where V 0.5, inact is the midpoint or half-maximal inactivation, and k is the slope factor. Using Clampfit 10 (Molecular Devices), activation kinetics were determined from a single exponential fit of the current activating phase. Concentration-response relationships were obtained by plotting normalized current amplitude as a function of drug concentration and fitted using a logistic equation. All voltage potentials were adjusted for liquid junction potential. Unless stated otherwise, all data are represented as mean 6 S.E.M. The statistical significance between two groups was evaluated by student's t test. One-way analysis of variance followed by Bonferroni's post hoc test was used to compare three or more groups. Differences were considered statistically significant if P , 0.05.
Chemicals and Drugs. a-Conotoxin Vc1.1 was synthesized as described previously (Schnolzer et al., 1992; Luo et al., 1998; Clark et al., 2006 Clark et al., , 2008 . It was provided as a stock concentration of ∼1 mM in H 2 O by Dr. Ray Norton (Monash University, Melbourne, VIC, Australia). Baclofen, GABA, and pertussis toxin (PTX) were purchased from Sigma-Aldrich (St. Louis, MO), and CGP54626 ([S-(R*,R*)](-3-{[1-(3,4-dichlorophenyl)ethyl]amino}-2-hydroxypropyl) [(3,4) -cyclohexylmethyl] phosphinic acid hydrochloride) was purchased from Tocris Bioscience (Bristol, UK). All drugs were diluted to the appropriate final concentration and applied via perfusion in the bath solution. Vc1.1 was applied at a concentration of 200 nM for maximum response. As a positive control for functional expression of GABA B R with Ca v 2.2 channels, baclofen was applied after Vc1.1 application. Only cells responding to baclofen with at least 50% peak current inhibition were included in our analysis.
Results
Comparison of Vc1.1-Dependent Inhibition with Canonical GABA-Dependent Inhibition of Ca v 2.2 Channels. Confirming previous reports (Cuny et al., 2012) , a bath application of Vc1.1 (200 nM) reduced peak Ba 21 current (I Ba ) amplitude by 41.5 6 5.3 (n = 12) in HEK293 cells stably expressing human Ca v 2.2 (a 1B , b 1b , and a 2 d) and coexpressing human GABA B1a/B2 receptors (Fig. 1, A and B) . The concentrationresponse relationship for Vc1.1 inhibition of Ca v 2.2 has an IC 50 of 19.1 nM, which is approximately 10-fold higher than that reported for rat DRG neurons (Callaghan et al., 2008) (Fig. 1D ). This shift most likely reflects differences between human and rat GABA B R. However, typically, 200 nM Vc1.1 was used as it gave a maximal response with either rat or human GABA B R. Inhibition of I Ba by baclofen was maximal in ,1 minute and rapidly reversed upon washout. By contrast, Vc1.1 inhibition was slower, reaching steady state after ∼15 minutes. Furthermore, Vc1.1 inhibition of I Ba was not reversed following Bar graph comparing Vc1.1 and baclofen inhibition of peak current amplitude. Vc1.1 (200 nM) inhibition of peak current was not affected by the mutation (52.3 6 8.6% compared with 47.1 6 14.4% for control; P = 0.75). However, baclofen (50 mM) inhibition was significantly reduced by the mutation (14.7 6 3.0% compared with 43.3 6 8.6% for control). Number of experiments is indicated in parentheses. Data represent mean 6 S.E.M. **P , 0.01. GB-WT, wild-type GABA B R.
washout of the Vc1.1 peptide, but the amplitude was subsequently further reduced by application of baclofen (Fig. 1 , B and C). Taken together, these results suggest Vc1.1 inhibition of Ca v 2.2 channels occurs via a signaling pathway different from GABA/baclofen-mediated inhibition.
Baclofen and GABA both bind to the extracellular Venus Fly Trap of the GABA B1 subunit (Galvez et al., 1999 (Galvez et al., , 2000 . Therefore, we introduced an alanine substitution at serine 270 of the GABA B1a subunit to test whether Vc1.1 interacts with this binding site. S270A was shown previously to substantially and presence of baclofen (n = 7) and Vc1.1 (n = 6). Lower panel: voltage dependence of Ca V 2.2 activation in the absence (control) and presence of Vc1.1 (200 nM) and baclofen (50 mM). Ca V 2.2-mediated currents were evoked by step depolarization from a holding potential of -80 to +50 mV in 5-mV increments at 0.1 Hz. Baclofen shifted the V 0.5 activation to more depolarized potentials (+3.7 6 1.5 mV; n = 7), whereas Vc1.1 did not change V 0.5 activation (-5.1 6 0.9 mV; n = 8) compared with control (-6.3 6 0.7 mV; n = 8). Data represent mean 6 S.E.M. (B) Analysis of Ca V 2.2 activation using a tail current protocol. Upper panel: representative superimposed whole-cell currents obtained in the absence and presence of baclofen from a cell expressing Ca v 2.2 and GABA B R. Tail currents were measured upon repolarization to 260 mV immediately following depolarizing test pulses from 240 to +55 mV in 5-mV increments. Lower panel: Ca v 2.2 activation curves obtained from tail currents were fitted with the sum of two Boltzmann functions. Baclofen shifted both V 0.5 and k, whereas Vc1.1 did not. The parameters of the major Boltzmann function obtained from the best fit to the data were V 0.5, act = +8.9 6 2.6 mV and k = 5.8 6 1.2 mV (n = 8) under control conditions; V 0.5, act = +7.8 6 2.1 mV and k = 4.5 6 2.4 mV (n = 6) in the presence of Vc1.1; and V 0.5, act = +17.4 6 3.8 mV and k = 8.4 6 1.5 mV (n = 4) in the presence of baclofen. (C) Ca v 2.2 SSI curves obtained in the absence and presence of Vc1.1 (200 nM) and baclofen (50 mM). Peak current amplitudes following a 10-second prepulse at varying potentials were normalized to the maximum peak current amplitude recorded at +5 mV, with a prepulse of -120 mV. V 0.5, inact was unchanged in the presence of baclofen (-64.3 6 1.8 mV; n = 7) compared with control (-65.5 6 0.6 mV; n = 8), whereas Vc1.1 shifted V 0.5, inact to -78.8 6 0.5 mV (n = 10), which was significantly different to control (P , 0.05, one-way analysis of variance). Data represent mean 6 S.E.M. (D) SSI of Ca v 2.2 channels was further investigated in individual cells in the absence (control) and presence of Vc1.1 (200 nM). Upper left panel: voltage protocol to evaluate SSI of Ca v 2.2. Upper right panel: ratio of peak current amplitudes elicited by depolarizing test pulses to +10 mV separated by a 10-second prepulse at 2110, 280, and 250 mV (P1/P2) in the absence (control) and presence of Vc1.1. Holding potential is -80 mV. In the presence of Vc1.1 and at a prepulse potential of -110 mV, P2/P1 was reduced from 1.33 6 0.07 to 1.01 6 0.01 (n = 11; P , 0.01, paired t test), and at -50 mV, P2/P1 was reduced from 0.55 6 0.03 to 0.43 6 0.03 (n = 11; P , 0.01). Data represent mean 6 S.E.M. Lower panel: representative superimposed current traces evoked by step depolarization to +10 mV (P2) following 10-second prepulses to -110, -80, and -50 mV in the absence (s) and presence of Vc1.1 (j).
Mechanism of Ca v 2.2 Inhibition Revealed by a-Conotoxin Vc1.1 reduce agonist and antagonist binding affinities to the rat GABA B R (Galvez et al., 1999) . As expected, S270A significantly reduced baclofen inhibition of Ca v 2.2-mediated currents (14.7 6 3.0%; n 5 8) compared with wild-type GABA B R (43.3 6 8.6%; n 5 6; P , 0.05). However, the S270A mutation in GABA B1a did not significantly alter Vc1.1-dependent inhibition of Ca v 2.2 currents (47.1 6 14.4%; n 5 7), and was similar to wild-type GABA B R (52.3 6 8.6%; n 5 6; P 5 0.75) (Fig. 2) . We therefore tested another mutation, S246A, in the Venus Fly Trap domain of GABA B1a , which causes complete insensitivity to baclofen and GABA (Galvez et al., 2000) . Expression of GABA B1a -S246A with GABA B2 abolished baclofen-dependent inhibition of Ca v 2.2 currents (2.4 6 4.8%; n 5 6), as compared with wild-type GABA B R (76.9 6 12.5%; n 5 5). In contrast, Vc1.1 continued to inhibit Ca v 2.2 currents in cells coexpressing GABA B1a -S246A/ GABA B2 (26.6 6 7.9%; n 5 6). Inhibition was to a similar extent as that observed at wild-type GABA B R (30.4 6 1.8%; n 5 4), supporting our findings obtained with the S270A mutant. Vc1.1 inhibition of Ca v 2.2, however, was strictly dependent on coexpression with the GABA B R subunits (Fig. 1C) and consistent with previous results (Cuny et al., 2012) . These findings raise the possibility that Vc1.1 interacts with a different region of the GABA B R. In rat DRG neurons, the selective GABA B R antagonists CGP54626 and CGP55845 blocked Vc1.1 inhibition of Ca v 2.2 currents (Callaghan et al., 2008) , suggesting that these receptor antagonists interfere with Vc1.1 binding. In HEK293 cells expressing GABA B1 -S270A, CGP54626 was inactive and unable to antagonize Vc1.1 inhibition of Ca v 2.2 (n 5 3; data not shown). This is consistent with previous studies showing that the S270A mutation prevents binding of CGP54626 to GABA B R (Galvez et al., 1999; Geng et al., 2013) , and suggests that CGP54626 and CGP55845 occlude Vc1.1 binding to a site physically distinct from S270 and S246 of GABA B1 .
GABA B R-dependent inhibition of voltage-gated calcium channels has been examined extensively (Tedford and Zamponi, 2006) . This form of inhibition typically involves Gbg subunits binding to Ca v channels, shifting the voltage dependence of activation and slowing the activation kinetics. In addition, prepulse potentiation can antagonize Gbg-dependent inhibition of Ca v channels (Ikeda, 1996; Weiss et al., 2007) . We next examined if these features were also observed with Vc1.1-dependent inhibition. The voltage dependence and kinetics of activation/inactivation of Ca v 2.2 channels were analyzed in the presence of Vc1.1 or baclofen. Similar to previous studies (Jones et al., 1997; Colecraft et al., 2000) , baclofen shifted the halfmaximum activation (V 0.5, act ) of the conductance-voltage relationship by 110.0 mV (13.7 6 1.5 mV; n 5 7) as compared with that of control (-6.3 6 0.7 mV; n 5 8) ( Fig. 3A ; Table 1 ). By contrast, Vc1.1 did not alter the I-V relationship or voltage dependence of activation, with a V 0.5, act of -5.1 6 0.9 mV (n 5 6) ( Fig. 3A ; Table 1 ). We also analyzed the activation curves generated from Ca v 2.2 tail currents in the presence of baclofen or Vc1.1 (Fig. 3B) . The normalized peak tail current amplitudes were fitted with the sum of two Boltzmann functions (Lin et al., 2004; Castiglioni et al., 2006) . In the presence of baclofen, Ca v 2.2 channels were activated at significantly more depolarized voltages than in control conditions. Baclofen, but not Vc1.1, caused a shift in both the V 0.5 and k of each component of the Boltzmann fit ( Fig. 3B ; Table 1 ).
We next examined whether Vc1.1 inhibition altered the voltage dependence of SSI of Ca v 2.2. We used a 10-second prepulse at varying potentials to evaluate SSI. This prepulse duration was sufficient to allow complete recovery from inactivation. The inactivation curve obtained in the presence of Vc1.1 gave a half-maximal inactivation (V 0.5, inact ) of -78.8 6 0.5 mV (n 5 10), which was ∼13 mV more hyperpolarized than that of control (-65.5 6 0.6 mV; n 5 8; P , 0.05) ( Fig. 3C ; Table 1 ). Because of this shift in voltage, we examined the extent of Vc1.1-dependent inhibition produced by the shift in SSI. Therefore, we investigated SSI in individual HEK293 cells with prepulses of -110, -80, and -50 mV in the absence and presence of Vc1.1. Vc1.1 significantly reduced P2/P1 at both -50 and -110 mV (P , 0.01, paired t test) (Fig. 3D) . The shift in voltage dependence of inactivation over a wide range of prepulse potentials may account, in part, for Vc1.1 inhibition of Ca v 2.2 channels. Thus, Vc1.1 significantly affected SSI by shifting the inactivation curve to more hyperpolarized potentials.
We next examined the kinetics of activation after Vc1.1 inhibition of Ca v 2.2 channels. We measured the time constant of activation (t) of the Ca v 2.2 current in the absence (control) and then presence of baclofen or Vc1.1 (Fig. 4, A and B) . Baclofen (50 mM) significantly increased t from 1.63 6 0.18 milliseconds to 2.13 6 0.36 milliseconds (n 5 7; P 5 0.022, paired t-test) (Fig. 4C) . These values were comparable to those in previous reports (Bean, 1989; Toselli and Taglietti, 1993) . Studies using prepulse facilitation to examine the involvement of Gbg in Ca v 2 modulation also reported similar changes in the kinetics of activation (Doupnik and Pun, 1994; Ikeda, 1996) . In contrast, Vc1.1 (100 nM) significantly reduced t from 1.69 6 0.25 milliseconds to 1.26 6 0.23 milliseconds (n 5 8; P , 0.05). Thus, these results show that Vc1.1 inhibition produces the opposite effect on the kinetics of Ca v 2.2 activation. Baclofen slows activation, whereas Vc1.1 speeds activation.
Previous studies suggested that binding of Gbg to the poreforming Ca v a subunit and the subsequent slowing of activation are reversed by a strong depolarizing prepulse (Bean, 1989; Ikeda, 1996; Furukawa et al., 1998; Zamponi and Currie, 2013) . We therefore compared the effect of prepulse facilitation on GABA-and Vc1.1-dependent inhibition of Ca v 2.2 channels. In the absence of an agonist, a prepulse (pp) to 1120 mV led to an increase in the current amplitude evoked by the test pulse (20.9 6 1.9%; n 5 6) compared with the current amplitude recorded in the absence of a prepulse. This observation suggests that some basal inhibition of Ca v 2.2 occurs in HEK293 cells, which is similar to previous reports of Gbg modulation of Ca v 2.2 in the absence of GPCR activation (Meza and Adams, 1998; McDavid and Currie, 2006) . As expected, the prepulse to 1120 mV significantly relieved GABA-dependent inhibition of peak current from 64 6 4% (-pp) to 4 6 5% (1pp) (n 5 8; P , 0.05) (Fig. 5B) . Remarkably, a prepulse to 1120 mV did not significantly relieve Vc1.1 inhibition, which was 50 6 11% (-pp) compared with 36 6 6% (1pp) (n 5 5; P 5 0.283) (Fig. 5D ). Taken together, these experiments demonstrate that Vc1.1 inhibition differs from that of GABA/baclofen modulation of Ca v 2.2 channels in the voltage dependence of activation and inactivation, time course of activation, and sensitivity to recovery from prepulse potentiation. We therefore suggest that Vc1.1 inhibits Ca v 2.2 channels via a novel mechanism that does not involve Gbg G proteins.
Unique Role for G i/o G Proteins in Vc1.1 Inhibition of Ca v 2.2 Channels. To elucidate the signaling pathway(s) underlying Vc1.1-dependent inhibition of Ca v 2.2 channels, we first explored the role of PTX-sensitive G i/o G proteins. G i/o G proteins are essential components of GABA inhibition of Ca v 2.2 channels via GABA B Rs (Tedford and Zamponi, 2006; Katada, 2012) . PTX ADP ribosylates the Ga i/o subunit, uncoupling it from the receptor (Katada, 2012) . To examine the potential role of G i/o G proteins in Vc1.1-dependent inhibition of Ca v 2.2, we treated HEK293 cells coexpressing The depolarizing prepulse to +120 mV relieved GABA inhibition of peak current amplitude but did not significantly affect inhibition by Vc1.1. The outward current in response to the 50-millisecond prepulse to +120 mV has been blanked to better display the inward current. (D) Bar graph of GABA's inhibition of average peak current amplitude in the absence [64.0 6 4.0% (-pp)] and presence [4.0 6 5.0% (+pp)] of prepulse. The prepulse significantly relieved peak current amplitude (***P , 0.001, unpaired t test) in the presence of GABA, but did not change Vc1.1 inhibition of peak current amplitude [50.0 6 11.0 (-pp) to 36.0 6 6.0% (+pp)]. Number of experiments is indicated in parentheses. Data represent mean 6 S.E.M. (E) Peak inward current amplitude in response to a depolarizing test pulse to +5 mV plotted as a function of time in the absence and presence of Vc1.1 and GABA, as indicated. Closed symbols (d, -pp) represent peak current amplitude without a preceding prepulse, whereas open symbols (s, +pp) represent peak current amplitude following prepulse.
human GABA B Rs and Ca v 2.2 channels with PTX (3 mg/ml) for 16 hours. As expected, PTX almost completely prevented baclofen-dependent inhibition of Ca v 2.2 currents (5.0 6 2.3%; n 5 4), as compared with untreated controls (70.7 6 2.3%; n 5 11; P , 0.05, unpaired t test). Similarly, PTX attenuated Vc1.1 (200 nM) inhibition of peak Ca v 2.2 currents (0.9 6 3.5%; n 5 6) compared with control (42.0 6 5.7%; n 5 7; P , 0.05, unpaired t test) (Fig. 6) . Therefore, it appears Vc1.1 inhibition of Ca v 2.2 channels requires G i/o G protein coupling with GABA B Rs (see also Callaghan et al., 2008) .
We next examined whether activating Ga i/o through the GABA B R is also needed for Vc1.1-dependent inhibition of Ca v 2.2 channels. Previously, Binet et al. (2007) demonstrated that an arginine to aspartate mutation in the third transmembrane segment of GABA B2 dramatically reduces G protein activation. Consistent with such an effect, baclofen inhibition of the peak current amplitude in HEK293 cells coexpressing GABA B2 -R576D/GABA B1a and Ca v 2.2 channels was decreased to 11.2 6 4.3% (n 5 7), compared with a control peak current amplitude of 64.7 6 4.0% (n 5 6; P , 0.05).
Surprisingly, Vc1.1-dependent inhibition persisted in the presence of GABA B2 -R576D. Here, Vc1.1 decreased peak current amplitude by 35.6 6 8.8% (n 5 8), and this did not differ significantly from that of wild-type GABA B R (52.9 6 8.9%; n 5 6; P 5 0.204) (Fig. 7) . Thus, Vc1.1 inhibition of Ca v 2.2 channel current involves activation of GABA B Rs through a novel mechanism that requires Ga i/o G proteins (i.e., PTX sensitive) but not the canonical pathway for stimulating Ga i/o .
Important Role for the C-Terminal Domain of the GABA B1a Subunit in Vc1.1 Inhibition of Ca v 2.2 Channels. The observation that Vc1.1 inhibition occurred even with the R576D mutation in GABA B2 shifted our focus to other regions of the GABA B R. The C-terminal domain of the GABA B1a subunit contains an endoplasmic reticulum retention signal, a coiled-coil domain for binding with GABA B2 Vc1.1 inhibition was significantly less in cells pretreated with PTX (0.9 6 3.5%) than in untreated cells (42.0 6 5.7%). Similarly, baclofen inhibition was significantly less in cells pretreated with PTX (5.0 6 2.3%) than in untreated cells (70.7 6 2.3%). Number of experiments is indicated in parentheses. Data represent mean 6 S.E.M. ***P , 0.001, unpaired t test. GB-WT, wild-type GABA B R. Lower case letters represent times at which the superimposed current traces were obtained. (D) Bar graph comparing Vc1.1 and baclofen inhibition of peak current amplitude with coexpressed wild-type GABA B R and mutated GABA B R subunits. Vc1.1 inhibition of the peak current was not affected by the mutation (GABA B2 -R576D, 52.9 6 8.9%; control, 41.1 6 6.1%) but baclofen inhibition of the peak current was significantly reduced (GABA B2 -R576D, 11.2 6 4.3%; control, 64.8 6 4.0%). Number of experiments is indicated in parentheses. Data represent mean 6 S.E.M. ***P , 0.001, unpaired t test. GB-WT, wild-type GABA B R. and shielding the endoplasmic reticulum retention signal, and a putative domain in the proximal C terminus (PCT) that interacts with Ca v channels (Laviv et al., 2011) . To examine the role of the coiled-coil domain in Vc1.1 inhibition, we truncated the C terminus of the GABA B1a receptor subunit from S887 (GABA B1a -D887). Compared with wild-type GABA B R, coexpression of GABA B1a -D887 with GABA B2 and Ca v 2.2 channels did not significantly alter Vc1.1-dependent inhibition of the peak current [37.9 6 5.6% (n 5 11) compared with 24.9 6 6.9% (n 5 7; P 5 0.171, unpaired t test)]. Similarly, baclofen inhibition of the peak current was not affected by GABA B1a -D887 deletion (62.0 6 7.3%, n 5 7, for D877 compared with 57.5 6 5.2%, n 5 11, for control; P 5 0.613) (Fig. 8, B and E) . Truncating the GABA B1a C-terminal domain at G863 (D863), which removes the PCT as well as the coiled-coil domain, significantly reduced Vc1.1 inhibition of the peak current (9.5 6 4.0%, n 5 12, for D863 compared with 37.9 6 5.6%, n 5 11, for control; P , 0.05) (Fig. 8, C and E) . However, baclofendependent inhibition was unaffected by the truncation at G863 (Fig. 8, C and E) .
To further explore the role of the PCT, we examined the effect of specifically deleting 21 amino acids within this domain (R857-S877; ΔPCT) on Vc1.1 inhibition. In HEK293 cells coexpressing Ca v 2.2 and GABA B1a -ΔPCT/GABA B2 -wt, Vc1.1 inhibition of the peak current was significantly less (5.3 6 3.9%; n 5 5) than that of cells coexpressing wild-type GABA B R (37.9 6 5.7%; n 5 11; P , 0.05). In contrast, baclofen inhibition of the peak current in cells expressing the GABA B1a -ΔPCT mutant was unchanged (60 6 2.7%, n 5 5, for ΔPCT compared with 57.5 6 5.2%, n 5 11, for control; P . 0.05) (Fig. 8, D and E) . These results suggest that the proximal C-terminal domain of GABA B1a is involved in Vc1.1-dependent inhibition of Ca v 2.2 channels. Discussion a-Conotoxin Vc1.1 and GABA/Baclofen Differentially Inhibit Ca v 2.2. The GABA B R agonists, GABA and baclofen, are known to bind to the GABA B1 Venus Fly Trap, activating the heterodimer of GABA B1a/B2 and inhibiting Ca v 2.2 channels via a pathway involving Gbg subunits (Galvez et al., 1999) . Binding of Gbg to the Ca v a 1B pore shifts the channels from willing to reluctant gating states, thus changing the channel's inactivation to a hyperpolarized potential and slowing the rate of activation to reduce the peak current (Ikeda, 1996) . Prepulse potentiation can recover the inhibition produced by Gbg subunits (Zamponi and Currie, 2013) . Using an established HEK293 system that coexpresses GABA B R and Ca v 2.2 channels (Cuny et al., 2012) , we discovered that the mode of Vc1.1 inhibition is distinctly different from that of GABA/baclofen inhibition of Ca v 2.2 channels. (24.9 6 6.9%; n = 7) was not significantly different from that in wild-type GABA B R expressing cells (37.9 6 5.6%; n = 11). Vc1.1 inhibition of the peak current in HEK293T cells expressing GABA B1a -Δ863/GABA B2 -WT (9.5 6 4.0%; n = 12) or GABA B1a -ΔPCT/GABA B2 (5.3 6 3.9%; n = 5) was significantly different from that in wild-type GABA B R expressing cells (37.9 6 5.6%; n = 11; P , 0.05). Baclofen inhibition of peak currents was the same in GABA B1a -Δ887/GABA B2 -WT (62.0 6 7.3%; n = 7), GABA B1a -Δ863/ GABA B2 -WT (56.6 6 3.5%; n = 10), and GABA B1a -ΔPCT/GABA B2 -WT expressing cells (60.7 6 2.7%; n = 5). Data represent mean 6 S.E.M. **P , 0.01, one-way analysis of variance. GB-WT, wild-type GABA B R.
Mechanism of Ca v 2.2 Inhibition Revealed by a-Conotoxin Vc1.1
First, GABA and baclofen inhibition of Ca v 2.2 via GABA B R activation is predominantly voltage dependent (Ikeda, 1996) , that is, activation is slowed and shifted to more depolarized potentials. In comparison, Vc1.1 inhibition of Ca v 2.2 channels does not shift the voltage dependence of activation, regardless of whether Gbg is activated, and the kinetics of activation are accelerated following Vc1.1 inhibition. Second, Vc1.1 inhibition of Ca v 2.2 via GABA B R activation cannot be reversed by peptide washout or strong depolarization. These findings indicate that Vc1.1 inhibition of Ca v 2.2 channels does not occur via the traditional pathway of activated Gbg voltagedependent inhibition.
The slow onset and recovery of Vc1.1 inhibition of Ca v 2.2-mediated currents are suggestive of a phosphorylationdependent mechanism, similar to that of tyrosine kinasedependent Gbg-independent inhibition of Ca v 2.2-e37a (Gray et al., 2007; Raingo et al., 2007) . The Ca v 2.2-e37a splice variant is predominantly expressed in nociceptive DRG neurons where it is implicated in nociception transmission. The more prevalent Ca v 2.2-e37b variant is widely distributed in the central nervous system (Altier et al., 2007) . Interestingly, the one known underlying cause of decreased morphine efficacy is thought to be due to altered Ca v 2.2-e37a to Ca v 2.2-e37b ratios in DRG neurons (Andrade et al., 2010) . However, Vc1.1 affects both Ca v 2.2 splice variants as inhibition was observed in both the stable Ca v 2.2 cell line (expressing e37b) and in cells transiently cotransfected with Ca v 2.2-e37a. This rules out a role for tyrosine kinase phosphorylation at exon 37a in Vc1.1 inhibition. Another potential mechanism of action is GABA B Ractivated internalization of the GABA B R-Ca v 2.2 complex. However, it was recently shown that b-arrestin, which is important for receptor internalization, is not bound to GABA B R (Sudo et al., 2012) . Furthermore, surface biotinylation showed that GABA B R cell surface expression was not affected by exposure to Vc1.1 (Cuny et al., 2012) .
However, one common feature of GABA/baclofen-and Vc1.1-dependent inhibition is the requirement for G i/o G proteins. Pretreatment with PTX abolished Vc1.1 inhibition of Ca v 2.2 channels, indicating that G i/o proteins may be involved. Moreover, we previously showed that GDP-b-S also prevented Vc1.1 inhibition of HVA calcium channel currents (Callaghan et al., 2008; Berecki et al., 2014) . However, Vc1.1 inhibited Ca v 2.2 channels in cells coexpressing Ca v 2.2 and GABA B R constructs with known GABA/baclofen binding sites removed (GABA B1 -S270A and GABA B1 -S246A) or reduced activation of G proteins (GABA B2 -R576D). Thus, we conclude that PTX-sensitive G proteins are required for Vc1.1 inhibition, but Vc1.1 appears to act as an allosteric modulator, similar to the biased signaling mechanisms described for other receptors (Wootten et al., 2013; Wisler et al., 2014) .
Vc1.1 Inhibition of Ca v 2.2 Via GABA B R Activation Is Dependent on the GABA B1a Subunit PCT Domain. Our findings raise the question of how Vc1.1 activates GABA B R to inhibit Ca v 2.2 channels without activating G proteins. One explanation may be direct contact between GABA B R and Ca v 2.2, and such an interaction could involve G proteins. GABA B R physically interacts with the GIRK channel to modulate its function via G proteins (Fowler et al., 2007; Ciruela et al., 2010) . However, Vc1.1 does not appear to activate GIRK channels (T. Huynh and P. Slesinger, unpublished observation; see also McIntosh et al., 2009) . Laviv et al. (2011) showed functional fluorescence resonance energy transfer coupling of GABA B R with Ca v 2.2 via G proteins. This was dependent on the PCT domain of the GABA B1a subunit (Laviv et al., 2011) . Also, heterodimeric GABA B receptors can form higher ordered oligomers that may regulate GABA B R function (Comps-Agrar et al., 2011) . We hypothesize that GABA B R and Ca v 2.2 form a complex with G proteins, and this interaction is dependent on the GABA B1a PCT domain (Fig. 9) . Interestingly, deleting the GABA B1a PCT domain reduced Vc1.1 but not GABA/baclofen inhibition of Ca v 2.2 channels. This suggests the PCT domain may couple GABA B R and Ca v 2.2 during Vc1.1 activation of GABA B Rs. The PCT domain may act as the anchoring site for the channel, and if so, its deletion would prevent the formation of a GABA B RCa v 2.2 channel complex. In hippocampal neurons, the PCT domain of the GABA B receptor was essential for the formation of a Ca v 2.2 and G protein complex (Laviv et al., 2011) . We speculate the PCT domain serves the same role for enabling Vc1.1 inhibition. It will be interesting to investigate whether Vc1.1 produces a change in fluorescence resonance energy transfer between GABA B R and Ca v 2.2, indicating coupling and physical contact between GPCR and the channel.
Physiologic Significance of Bias to GABA B R Signaling. Our results show the PCT domain of the GABA B1a subunit is integral to a-conotoxin Vc1.1 activation of GABA B R and inhibition of Ca v 2.2 channels. In contrast, the PCT is not required for GABA/baclofen Gbg-facilitated channel inhibition. GABA B R-biased signaling upon Vc1.1 activation is a newly identified mechanism for presynaptic inhibition of neurotransmitter release at central synapses. A comparison of baclofen and Vc1.1-mediated inhibition of Ca v 2.2 via GABA B R activation is summarized in Table 2 . It is also distinct from that recently reported for Ca v 2.3 inhibition by a-conotoxin Vc1.1. Ca v 2.3 inhibition is voltage independent and mediated by specific c-Src kinase-dependent phosphorylation sites in the C-terminus of the channel (Berecki et al., 2014) .
GABA B Rs are widely distributed in the central and peripheral nervous systems. Baclofen, a selective GABA B R agonist, has been used to treat various neurologic disorders, including spasticity, chronic pain, and alcoholism (Hudgson and Weightman, 1971; Hering-Hanit, 1999; Balerio and Rubio, 2002; Garbutt and Flannery, 2007) . However, it causes numerous side effects due to its indiscriminate activation of multiple GABA B R signaling pathways (Bowery, 2007) . In contrast, a-conotoxin Vc1.1 activates a distinct voltage-independent GABA B R-Ca v 2.2 signaling pathway that requires the GABA B1a PCT domain to couple GABA B R to Ca v 2.2, ultimately inhibiting Ca v 2.2 channels. This GABA B R-biased signaling mechanism likely contributes to the superior selectivity and analgesic properties of Vc1.1 (Klimis et al., 2011) .
Our enhanced understanding of the molecular mechanism of Vc1.1 inhibition of Ca v 2.2 channels and its analgesic properties, along with the fact that it did not cause observable side effects in animal models of chronic pain, provides a platform from which analgesic conotoxins could be developed into safe and effective drugs (Satkunanathan et al., 2005; Vincler et al., 2006; Klimis et al., 2011) .
